DE102005024494A1 - Verwendung von Cyanopyrimidinen - Google Patents

Verwendung von Cyanopyrimidinen Download PDF

Info

Publication number
DE102005024494A1
DE102005024494A1 DE102005024494A DE102005024494A DE102005024494A1 DE 102005024494 A1 DE102005024494 A1 DE 102005024494A1 DE 102005024494 A DE102005024494 A DE 102005024494A DE 102005024494 A DE102005024494 A DE 102005024494A DE 102005024494 A1 DE102005024494 A1 DE 102005024494A1
Authority
DE
Germany
Prior art keywords
alkyl
mmol
preparation
compounds
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE102005024494A
Other languages
German (de)
English (en)
Inventor
Martin Dr. Hendrix
Frank Dr. Wunder
Adrian Dr. Tersteegen
Johannes-Peter Dr. Stasch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Priority to DE102005024494A priority Critical patent/DE102005024494A1/de
Priority to EP06742947A priority patent/EP1890702A1/fr
Priority to PCT/EP2006/004639 priority patent/WO2006125554A1/fr
Publication of DE102005024494A1 publication Critical patent/DE102005024494A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE102005024494A 2005-05-27 2005-05-27 Verwendung von Cyanopyrimidinen Withdrawn DE102005024494A1 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DE102005024494A DE102005024494A1 (de) 2005-05-27 2005-05-27 Verwendung von Cyanopyrimidinen
EP06742947A EP1890702A1 (fr) 2005-05-27 2006-05-17 Utilisation de cyanopyrimidines pour traiter des troubles cardio-vasculaires
PCT/EP2006/004639 WO2006125554A1 (fr) 2005-05-27 2006-05-17 Utilisation de cyanopyrimidines pour traiter des troubles cardio-vasculaires

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005024494A DE102005024494A1 (de) 2005-05-27 2005-05-27 Verwendung von Cyanopyrimidinen

Publications (1)

Publication Number Publication Date
DE102005024494A1 true DE102005024494A1 (de) 2006-11-30

Family

ID=36888992

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102005024494A Withdrawn DE102005024494A1 (de) 2005-05-27 2005-05-27 Verwendung von Cyanopyrimidinen

Country Status (3)

Country Link
EP (1) EP1890702A1 (fr)
DE (1) DE102005024494A1 (fr)
WO (1) WO2006125554A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080083188A (ko) * 2006-01-11 2008-09-16 아스트라제네카 아베 모르폴리노 피리미딘 유도체 및 요법에서의 그 유도체의용도
MX2009002046A (es) * 2006-08-24 2009-03-06 Astrazeneca Ab Derivados de morfolino pirimidina utiles en el tratamiento de trastornos proliferativos.
WO2008023180A1 (fr) * 2006-08-24 2008-02-28 Astrazeneca Ab Dérivés de morpholino pyrimidine utiles dans le traitement de désordres prolifératifs
AU2008273891B2 (en) 2007-07-09 2012-01-12 Astrazeneca Ab Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
WO2015185499A1 (fr) * 2014-06-06 2015-12-10 H. Lundbeck A/S Inhibiteurs pde9 présentant un squelette 1-benzyl-2,5,6,8-tétrahydro-3-oxo-2,7-naphtyridine-4-carbonitrile
CN109020837A (zh) * 2018-07-27 2018-12-18 广东省石油与精细化工研究院 一种2-取代苯基-乙脒盐酸盐的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR82004B (fr) * 1983-06-30 1984-12-12 American Home Prod
HN2002000317A (es) * 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
DE10156249A1 (de) * 2001-11-15 2003-05-28 Bayer Ag Regulation der cGMP-spezifischen Phosphodiesterase 9A
EP1573331A1 (fr) * 2002-12-09 2005-09-14 Bayer HealthCare AG Diagnostic et traitement de maladies associees a la phosphodiesterase 9a1(pde9a1)humaine
DE10328479A1 (de) * 2003-06-25 2005-01-13 Bayer Ag 6-Arylamino-5-cyano-4-pyrimidinone

Also Published As

Publication number Publication date
EP1890702A1 (fr) 2008-02-27
WO2006125554A1 (fr) 2006-11-30

Similar Documents

Publication Publication Date Title
JP7093438B2 (ja) Ｅｒｋ１及びｅｒｋ２の複素環式阻害剤並びに癌治療におけるその使用
JP5457476B2 (ja) 知覚力、集中力、学習力および／または記憶力の改善のために使用される６−アミノ−５−シアノ−ピリミジン−４−オン化合物
EP1534713B1 (fr) Pyrazolopyrimidines substituees par alkyle
MX2010011591A (es) Pirimidin-5-carboxamidas sustituidas 281.
WO2004018474A1 (fr) Pyrazolopyrimidines substituees par phenyle
EP1626971B1 (fr) Pyrazolopyrimidines substituees par 6-cyclylmethyle et 6-alkylmethyle
WO2004005291A1 (fr) Imidazotriazines heterocycliquement substituees
DE102005024494A1 (de) Verwendung von Cyanopyrimidinen
EA030569B1 (ru) Замещенные бициклические дигидропиримидиноны и их применение в качестве ингибиторов активности нейтрофильной эластазы
EP1599479A1 (fr) Imidazotriazines substituees
EP1644339B1 (fr) 6-arylamino-5-cyano-4-pyrimidinones en tant qu'inhibiteurs de la pde9a
EP1628980A1 (fr) Pyrazolopyrimidines substituees par 6-arylmethyle
DE102005024493A1 (de) Verwendung von Pyrazolopyrimidinen
DE102004004142A1 (de) 6-Cyclylmethyl- und 6-Alkylmethyl-substituierte Pyrazolopyrimidine
MXPA06007982A (en) 6-amino-5-cyano-pyrimidine-4-ones used for improving perception, power of concentration, learning efficiency, and/or memory power

Legal Events

Date Code Title Description
8181 Inventor (new situation)

Inventor name: STASCH, JOHANNES-PETER, DR., 42651 SOLINGEN, DE

Inventor name: WUTTKE, MARTINA, DR., 42111 WUPPERTAL, DE

Inventor name: TERSTEEGEN, ADRIAN, DR., 42115 WUPPERTAL, DE

Inventor name: HENDRIX, MARTIN, DR., 51519 ODENTHAL, DE

Inventor name: WUNDER, FRANK, DR., 42117 WUPPERTAL, DE

8139 Disposal/non-payment of the annual fee